Vertex Pharmaceuticals Inc
SWB:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
SWB:VX1
|
US |
|
F
|
Fuji Media Holdings Inc
SWB:FTN
|
JP |
|
T
|
Tencent Holdings Ltd
DUS:NNND
|
CN |
|
S
|
Silvercorp Metals Inc
AMEX:SVM
|
CA |
|
B
|
BP PLC
BMV:BPN
|
UK |
|
T
|
Tesla Inc
DUS:TL0
|
US |
|
CGN Power Co Ltd
OTC:CGNWF
|
CN |
|
A-Mark Precious Metals Inc
F:AND
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
506.26
EUR
According to Wall Street analysts, the average 1-year price target for 
VX1 is 506.26 EUR with a low forecast of 303.82 EUR and a high forecast of 606.43 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Gross Profit forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
What is the Pre-Tax Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
21%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 21%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
14%
The compound annual growth rate for Net Income over the next 8 years is 14%.